PE20141484A1 - Formulaciones peptidicas de liberacion controlada - Google Patents
Formulaciones peptidicas de liberacion controladaInfo
- Publication number
- PE20141484A1 PE20141484A1 PE2013002546A PE2013002546A PE20141484A1 PE 20141484 A1 PE20141484 A1 PE 20141484A1 PE 2013002546 A PE2013002546 A PE 2013002546A PE 2013002546 A PE2013002546 A PE 2013002546A PE 20141484 A1 PE20141484 A1 PE 20141484A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- preformulation
- peptidic
- formulations
- refers
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000004973 liquid crystal related substance Substances 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Abstract
SE REFIERE A UNA PREFORMULACION QUE COMPRENDE UNA MEZCLA DE BAJA VISCOSIDAD QUE COMPRENDE: a) 20-80% EN PESO DE UN DIACILGLICEROL Y/O UN TOCOFEROL; b) 20-80% EN PESO DE UNA FOSFATIDILCOLINA (PC); c) 5-20% EN PESO DE UN SOLVENTE MONO-ALCOHOLICO ORGANICO, BIOCOMPATIBLE; d) HASTA 20% EN PESO DE SOLVENTE POLAR TAL COMO AGUA, PROPILENGLICOL O MEZCLA DE LOS MISMOS; e) UN AGENTE ACTIVO PEPTIDICO TAL COMO UN ANALOGO DE SOMATOSTATINA; Y f) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO, EDTA O ACIDO CITRICO; DONDE LA RELACION DE COMPONENTES a:b ESTA DENTRO DEL RANGO 40:60 A 54:46; DONDE LA PREFORMULACION FORMA UNA ESTRUCTURA DE FASE CRISTALINA LIQUIDA LUEGO DEL CONTACTO CON FLUIDO ACUOSO EN EXCESO. SE REFIERE TAMBIEN A UN PROCESO PARA LA FORMACION DE DICHA PREFORMULACION, A DISPOSITIVOS Y KITS DE ADMINISTRACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489886P | 2011-05-25 | 2011-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141484A1 true PE20141484A1 (es) | 2014-10-31 |
Family
ID=46456496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002546A PE20141484A1 (es) | 2011-05-25 | 2012-05-25 | Formulaciones peptidicas de liberacion controlada |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US11433120B2 (es) |
| EP (2) | EP2714004B1 (es) |
| JP (2) | JP6265888B2 (es) |
| KR (1) | KR102066755B1 (es) |
| CN (2) | CN108283619B (es) |
| AR (1) | AR086577A1 (es) |
| AU (2) | AU2012260821B2 (es) |
| BR (1) | BR112013030104A8 (es) |
| CA (1) | CA2836847C (es) |
| CL (1) | CL2013003365A1 (es) |
| CO (1) | CO6900117A2 (es) |
| CR (1) | CR20130653A (es) |
| CU (1) | CU20130158A7 (es) |
| DK (1) | DK2714004T3 (es) |
| DO (1) | DOP2013000275A (es) |
| EA (1) | EA036213B1 (es) |
| EC (1) | ECSP13013107A (es) |
| ES (1) | ES2984717T3 (es) |
| FI (1) | FI2714004T3 (es) |
| GT (1) | GT201300292A (es) |
| HR (1) | HRP20240781T1 (es) |
| HU (1) | HUE067389T2 (es) |
| IL (1) | IL229376B (es) |
| LT (1) | LT2714004T (es) |
| MX (1) | MX361716B (es) |
| MY (1) | MY177820A (es) |
| NI (1) | NI201300127A (es) |
| PE (1) | PE20141484A1 (es) |
| PH (1) | PH12013502550A1 (es) |
| PL (1) | PL2714004T3 (es) |
| PT (1) | PT2714004T (es) |
| RS (1) | RS65702B1 (es) |
| SG (1) | SG194865A1 (es) |
| SI (1) | SI2714004T1 (es) |
| TW (1) | TWI624271B (es) |
| WO (1) | WO2012160213A1 (es) |
| ZA (1) | ZA201309653B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ551990A (en) * | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| US9107904B2 (en) * | 2012-04-05 | 2015-08-18 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| WO2013174978A1 (en) * | 2012-05-25 | 2013-11-28 | Camurus Ab | Somatostatin receptor agonist formulations |
| NZ704012A (en) | 2012-07-26 | 2017-09-29 | Camurus Ab | Opioid formulations |
| EP3326613A1 (en) | 2012-07-26 | 2018-05-30 | Camurus AB | Opioid formulations |
| US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| WO2018060213A1 (en) | 2016-09-27 | 2018-04-05 | Camurus Ab | Formulations containing a somatostatin receptor agonist |
| MX2019002999A (es) | 2016-09-15 | 2019-07-18 | Camurus Ab | Formulaciones de analogo de prostaciclina. |
| WO2018106859A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| AU2018370039A1 (en) * | 2017-11-15 | 2020-05-21 | Rhythm Pharmaceuticals, Inc. | Sustained release peptide formulations |
| KR20200140265A (ko) | 2018-03-02 | 2020-12-15 | 엘리시오 테라퓨틱스, 인크. | Cpg 양친매성 물질 및 이의 용도 |
| CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
| CN113993535B (zh) * | 2019-05-29 | 2025-03-14 | 卡姆拉斯公司 | 脂质控释组合物 |
| CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
| CA3217408A1 (en) * | 2021-05-04 | 2022-11-10 | Fredrik Tiberg | Compositions and methods for treating neuroendocrine tumors |
| WO2024263085A1 (en) * | 2023-06-20 | 2024-12-26 | Camurus Ab | Compositions and methods for treating acromegaly |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005046642A1 (en) * | 2003-11-07 | 2005-05-26 | Camurus Ab | Compositions of lipids and cationic peptides |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| NZ551990A (en) * | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| EP1778187B1 (en) | 2004-08-04 | 2012-05-23 | Camurus Ab | Compositions forming non-lamellar dispersions |
| GB0417388D0 (en) * | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| SI1845942T1 (sl) * | 2005-01-14 | 2014-06-30 | Camurus Ab | Gnrh analogne formulacije |
| AU2005325510B2 (en) * | 2005-01-21 | 2009-07-02 | Camurus Ab | Pharmaceutical lipid compositions |
| AU2006235183B2 (en) * | 2005-04-08 | 2011-02-10 | Amylin Pharmaceuticals, Llc | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| CA2609810C (en) * | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US8931272B2 (en) * | 2010-10-29 | 2015-01-13 | Ford Global Technologies, Llc | Method and system for limiting output of a boosted engine |
| WO2013083459A1 (en) * | 2011-12-05 | 2013-06-13 | Camurus Ab | Robust controlled-release peptide formulations |
| WO2013174978A1 (en) * | 2012-05-25 | 2013-11-28 | Camurus Ab | Somatostatin receptor agonist formulations |
| WO2018060213A1 (en) * | 2016-09-27 | 2018-04-05 | Camurus Ab | Formulations containing a somatostatin receptor agonist |
| US20230285502A1 (en) * | 2016-09-07 | 2023-09-14 | Camurus Ab | Mixtures and formulations |
-
2012
- 2012-05-25 PT PT127313153T patent/PT2714004T/pt unknown
- 2012-05-25 RS RS20240722A patent/RS65702B1/sr unknown
- 2012-05-25 EP EP12731315.3A patent/EP2714004B1/en active Active
- 2012-05-25 CA CA2836847A patent/CA2836847C/en active Active
- 2012-05-25 ES ES12731315T patent/ES2984717T3/es active Active
- 2012-05-25 EA EA201391675A patent/EA036213B1/ru not_active IP Right Cessation
- 2012-05-25 FI FIEP12731315.3T patent/FI2714004T3/fi active
- 2012-05-25 HR HRP20240781TT patent/HRP20240781T1/hr unknown
- 2012-05-25 SI SI201232066T patent/SI2714004T1/sl unknown
- 2012-05-25 MX MX2013013401A patent/MX361716B/es active IP Right Grant
- 2012-05-25 HU HUE12731315A patent/HUE067389T2/hu unknown
- 2012-05-25 DK DK12731315.3T patent/DK2714004T3/da active
- 2012-05-25 US US14/117,994 patent/US11433120B2/en active Active
- 2012-05-25 CN CN201810174910.XA patent/CN108283619B/zh active Active
- 2012-05-25 AU AU2012260821A patent/AU2012260821B2/en active Active
- 2012-05-25 CN CN201280025151.1A patent/CN103702662B/zh active Active
- 2012-05-25 PL PL12731315.3T patent/PL2714004T3/pl unknown
- 2012-05-25 BR BR112013030104A patent/BR112013030104A8/pt not_active Application Discontinuation
- 2012-05-25 LT LTEPPCT/EP2012/059917T patent/LT2714004T/lt unknown
- 2012-05-25 SG SG2013083019A patent/SG194865A1/en unknown
- 2012-05-25 WO PCT/EP2012/059917 patent/WO2012160213A1/en active Application Filing
- 2012-05-25 KR KR1020137034307A patent/KR102066755B1/ko active IP Right Grant
- 2012-05-25 TW TW101118843A patent/TWI624271B/zh active
- 2012-05-25 MY MYPI2013004227A patent/MY177820A/en unknown
- 2012-05-25 PE PE2013002546A patent/PE20141484A1/es active IP Right Grant
- 2012-05-25 JP JP2014511911A patent/JP6265888B2/ja active Active
- 2012-05-25 EP EP24175676.6A patent/EP4427814A3/en active Pending
- 2012-05-28 AR ARP120101869A patent/AR086577A1/es unknown
-
2013
- 2013-11-11 IL IL22937613A patent/IL229376B/en active IP Right Grant
- 2013-11-22 GT GT201300292A patent/GT201300292A/es unknown
- 2013-11-22 CL CL2013003365A patent/CL2013003365A1/es unknown
- 2013-11-22 DO DO2013000275A patent/DOP2013000275A/es unknown
- 2013-11-22 NI NI201300127A patent/NI201300127A/es unknown
- 2013-11-25 CU CU2013000158A patent/CU20130158A7/es unknown
- 2013-12-09 PH PH12013502550A patent/PH12013502550A1/en unknown
- 2013-12-12 CR CR20130653A patent/CR20130653A/es unknown
- 2013-12-20 ZA ZA2013/09653A patent/ZA201309653B/en unknown
- 2013-12-20 CO CO13297046A patent/CO6900117A2/es unknown
- 2013-12-24 EC ECSP13013107 patent/ECSP13013107A/es unknown
-
2016
- 2016-04-06 AU AU2016202156A patent/AU2016202156B2/en active Active
-
2017
- 2017-11-29 JP JP2017228735A patent/JP6415673B2/ja active Active
-
2021
- 2021-06-17 US US17/350,363 patent/US20210308226A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141484A1 (es) | Formulaciones peptidicas de liberacion controlada | |
| CL2018003452A1 (es) | Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. | |
| AR106049A1 (es) | Formulaciones de liberación controlada | |
| PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
| CU24400B1 (es) | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
| PE20141297A1 (es) | Formulaciones peptidicas robustas de liberacion controlada | |
| GT201600060A (es) | Formulaciones de espuma y aparatos para suminstro | |
| AR083016A1 (es) | Formulaciones liquidas para la agricultura con una mejor estabilidad | |
| BR112017013471A2 (pt) | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. | |
| CO2019012814A2 (es) | Composición farmacéutica líquida estable | |
| CO2021016449A2 (es) | Composiciones terapéuticas estables en solventes polares aproticos y métodos de fabricación de las mismas | |
| AR099097A1 (es) | SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA | |
| PH12014502614A1 (en) | Somatostatin receptor agonist formulations | |
| MX2013009655A (es) | Reduccion de la precipitacion de acido sorbico. | |
| AR098351A1 (es) | Sistema ruptor doble para reducir los daños en las formaciones durante la fracturación | |
| CL2020000551A1 (es) | Formulación de uso tópico para el control y la prevención de parásitos en animales. | |
| PE20220416A1 (es) | Formulacion agricola | |
| PE20131029A1 (es) | Composicion pesticida | |
| CO2018000526A2 (es) | Concentrado que contiene alprostadil | |
| PE20171305A1 (es) | Formulaciones inyectables de paracetamol | |
| CO2018000525A2 (es) | Concentrado que contiene alprostadil | |
| ECSP12012340A (es) | Composicion pesticida | |
| CL2019002843A1 (es) | Formulación del inhibidor stat3. | |
| BR112016013172A2 (pt) | Formulações agroquímicas | |
| AR100815A1 (es) | Formulaciones parasiticidas transdérmicas, método, uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |